PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis (NCT06855329)
PRIME-PPF: PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
🩺 Plain-English Summary (8th-Grade Level)
This is a prospective, observational cohort study. Participants with non-idiopatic pulmonary fibrosis, interstitial lung disease (ILD) will be followed for 24 months to systematically collect clinical, imaging, and biospecimen data. The primary objective is to optimize progressive pulmonary fibrosis (PPF) classification and establish PPF incidence for key ILD subtypes. Additional exploratory objectives are to 1) Prospectively validate a novel PPF classifier and assess performance durability over time, and 2) Determine whether multi-dimensional PPF prediction outperforms component approaches.
Who can join: Review the eligibility criteria below.
Location: University of Colorado | Anschutz Medical Campus — Aurora, Colorado
Age range: 18 Years to 80 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (24 Sites)
- University of Colorado | Anschutz Medical Campus — Aurora, Colorado
- University of Massachusetts Chan Medical School — Worcester, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- Weill Cornell Medicine — New York, New York
- University of Texas Southwestern — Dallas, Texas
- University of Virginia — Charlottesville, Virginia
- University of Washington — Seattle, Washington
- Royal Prince Alfred Hospital — Camperdown, New South Wales
- Prince Charles Hospital — Brisbane, Queensland
- Austin Health — Melbourne, Victoria
- Medical University of Graz — Graz,
- University of British Columbia — Vancouver, British Columbia
- Charles University and Faculty Thomayer Hospital — Prague,
- Aarhus University Hospital — Aarhus,
- Bichat, APHP — Paris,
- Chu Pontchaillou — Rennes,
- Prüfzentrum der GWT am Lungenzentrum Coswig — Coswig, Saxony
- University Medical Center Mainz — Mainz,
- LMU Munich — Munich,
- Semmelweis University — Budapest,
- University College Dublin — Dublin, Ireland
- Rimini and Riccione Hospitals, AUSL Romagna — Rimini,
- Erasmus MC — Rotterdam, South Holland
- Hospital Universitario de La Princesa — Madrid,
📞 Contact the Study Coordinator
Phone: (508) 334-8685
Email: fernando.martinez1@umassmed.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Progressive Pulmonary Fibrosis
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis — Birmingham, Alabama
- Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) — Birmingham, Alabama
- SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers — Charleston, South Carolina
- An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL) — Birmingham, Alabama
Explore by condition: All Progressive Pulmonary Fibrosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.